Last checked at 3 Aug 2016 07:00
(AIM: SAR) | 3 August 2016 |
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
China and Hong Kong Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors
Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with Sareum's Aurora+FLT3 Kinase Inhibitor Programme.
These patents*describe compounds that inhibit the activity of Aurora and FLT3 kinase enzymes and the medical use of these compounds, particularly in the treatment of cancer. The granting of these patents means that Sareum will have approved patent protection in China and Hong Kong for its Aurora+FLT3 inhibitor programme. The Company announced that similar patents were to be granted in the USA and Europe in September 2015. Other major territories, including Japan, are expected to follow in due course.
Sareum's Aurora+FLT3 inhibitor programme targets acute myeloid leukaemia (AML) and other leukaemias and lymphomas. In disease models of AML, the preclinical development candidate molecule demonstrates greater than 98% tumour inhibition. Preclinical development studies to obtain approval for human clinical trials are being undertaken in collaboration with, and funded by, Hebei Medical University Biomedical Engineering Center (HMUBEC) in China.
* Chinese Patent Application no. 2013800135445, Hong Kong Patent no. 1204327
Sareum's CSO, Dr John Reader, commented: "These notifications of patent grants for Sareum in China and Hong Kong demonstrate the strength of intellectual property protecting our Aurora+FLT3 programme, and reinforces the patent position for HMUBEC, our development partner in China".
For further information:
Sareum Holdings plc |
|
Tim Mitchell | 01223 497 700 |
WH Ireland Limited (Nominated Adviser and Co-Broker) | |
Chris Fielding / Nick Prowting | 020 7220 1666 |
Hybridan LLP (Co-Broker) |
|
Claire Noyce / William Lynne | 020 3764 2341/2342 |
The Communications Portfolio (Media enquiries) |
|
Ariane ComstiveAriane.comstive@communications-portfolio.co.uk | 07785 922 354 |
Notes for editors:
Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes a programme in Phase I clinical trials and another undergoing pre-clinical IND-enabling studies.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and autoimmune disease research programmes. SKIL(R) can also generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk